Minerva Neurosciences (NERV)

Executive Summary

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for CNS disorders, with a lead asset, roluperidone (MIN-101), targeting negative symptoms of schizophrenia. The company has completed Phase 3 trials demonstrating efficacy in this high-unmet-need population, where no approved treatments exist. Minerva also has a Phase 2 asset, MIN-117, for major depressive disorder. Despite a mixed regulatory history, the company’s deep expertise in trial design and patient-centric endpoints positions it for potential value creation. With a current valuation of ~$282 million, Minerva represents a speculative opportunity predicated on regulatory success and commercial execution in a niche CNS market.

Upcoming Catalysts (preview)

• TBDFDA decision on roluperidone for negative symptoms of schizophrenia45% success
• TBDPotential partnership or licensing deal for MIN-117 or roluperidone55% success
• TBDInitiation of new clinical trial or pipeline expansion30% success